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Mitigating the scourge of non-alcoholic fatty liver disease in Ghana 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is fast be-
coming the leading cause of liver disease in Western 
countries, affecting 25% of the general population1 and 
increasing to 90% of obese individuals with diabetes 
and other features of the metabolic syndrome.2 Moreo-
ver, its prevalence is expected to continue to rise in par-
allel with the obesity epidemic due to the adoption of  
sedentary lifestyle and increased consumption of high 
fat diet.3 In the United States, NAFLD is expected to 
become the leading indication for liver transplantation 
(LT) within the next 10 years.4 NAFLD is currently 
considered to be a major health burden in developed 
countries and is gradually increasing in developing 
countries due to urbanization and change in lifestyle 
habits, particularly in the countries of Arabian Gulf 
(with the highest incidence in the world), but it cannot 
be ignored in West Africa, where the problem is becom-
ing steadily more prevalent. 
 
Primary liver cancer is a major complication of liver 
disease and a contributor to global cancer incidence and 
mortality.5 Worldwide, liver cancer is the fifth most 
common cancer and the second most frequent cause of 
cancer death in men, while in women it is the seventh 
most commonly diagnosed cancer and the sixth leading 
cause of cancer death.6 Major risk factors for hepatocel-
lular carcinoma (HCC) include hepatitis B virus (HBV) 
and hepatitis C virus (HCV) chronic infections, alcohol-
ic liver disease, and NAFLD.7 Several population-based 
studies conducted in various geographic areas have rec-
orded a significantly increased incidence of HCC in 
patients with diabetes and obesity.8-11 There is also 
growing evidence that suggests an increased risk of 
HCC in NAFLD patients.12-14  Under these circumstanc-
es, NAFLD-related HCC incidence is expected to in-
crease in the future. Ghana is a developing country, with 
limited access to regular screening and palliative care, 
prevalent comorbidities (e.g. Hepatitis B, HIV/AIDS), 
and risk factors (e.g. Alcohol use) all playing a role, the 
scourge of fatty liver disease cannot be overlooked. 
NAFLD is currently considered a major health burden 
in developed countries and is gradually increased in 




It is an umbrella of disorders defined by abnormal ac-
cumulation of triglycerides in the liver; and ranges from 
fatty liver alone (steatosis) to fatty liver with inflamma-
tion (steatohepatitis)15  
It can occur with use of alcohol (alcohol-related fatty 
liver) or in the absence of alcohol (non-alcoholic fatty 
liver disease (NAFLD).  
 
NAFLD is defined as the presence of ≥5% of hepatic 
steatosis (HS), in the absence of competing liver disease 
etiologies, such as chronic viral hepatitis, use of medica-
tions that induce steatosis and other chronic liver dis-
eases, such as autoimmune hepatitis, hemochromatosis, 
Wilson's disease, or significant alcohol consumption. It 
is one of the commonest causes of abnormal liver func-
tion tests (LFTs).  NAFLD is strongly associated with 
epidemic of obesity and type 2 diabetes mellitus 
(DM)16 and increasingly being recognised as the liver 
component of metabolic syndrome.17  Nonalcoholic 
steatohepatitis, a potentially serious form of the disease, 
is marked by liver inflammation, which may progress to 
scarring and irreversible damage. This damage is similar 
to the damage caused by heavy alcohol use. At its most 
severe, nonalcoholic steatohepatitis can progress to cir-
rhosis, liver failure and liver cancer. Obesity, type 2 
diabetes mellitus (T2DM), and dyslipidemia are the 
most common metabolic risk factors associated with 
NAFLD. Among the components of metabolic syn-
drome, current evidence strongly indicates obesity and 
diabetes as hepatocellular carcinoma (HCC) risk factors. 
There is also growing evidence that suggests an in-
creased risk of HCC in NAFLD patients, even surpas-
sing other aetiologies in some high-income countries. 
Epidemiologic data demonstrate a parallel rise in preva-
lence of obesity, diabetes, NAFLD, and HCC. As obesi-
ty and its related diseases have steadily afflicted larger 
populations, HCC incidence is expected to increase in 
the future. Pathophysiologic mechanisms that underlie 
NAFLD development and subsequent progression to 
nonalcoholic steatohepatitis and cirrhosis (insulin re-
sistance and hyperinsulinemia, oxidative stress, hepatic 
stellate cell activation, cytokine/adipocytokine signal-
ling pathways, and genetic and environmental factors) 
appear to play a significant role in the development of 
NAFLD-related HCC. However, a comprehensive view 
of molecular mechanisms linking obesity, T2DM, and 
NAFLD-related HCC, as well as the exact sequence of 
molecular events, is still not understood in its entirety. 
 
Mitigating the scourge of NAFLD 
Assessing and management of NAFLD can be a daunt-
ing task; NAFLD is prevalent in people in their 5th dec-
ade of life who often have multiple comorbidities such 




www.ghanamedj.org  Volume 51 Number 3 September 2017 99 
Improving provision of assessment and testing of those 
individuals at highest risk of developing liver disease, 
creating awareness and understanding of liver disease 
among primary and community care, and local govern-
ment partners to help detect early liver disease and 
make appropriate referral will go a long way in prevent-
ing late presentation of the disease with substantial 
morbidity and high mortality rates.   
 
A key challenge in the clinical care of NALFD patients 
in Ghana is the lack of safe, reliable, and cost-effective 
means of diagnosing and staging the disease. Fatty liver 
is frequently discovered incidentally during ultrasound, 
CT or MRI scanning and a proportion of these individu-
als may have advanced liver disease in spite of having 
normal LFTs. Currently, referral practices of these indi-
viduals are patchy and development of a robust risk 
assessment and referral guideline should be implement-
ed. Liver fibrosis is believed to be the most important 
factor for progression to cirrhosis18, but as yet there is 
no ideal tool for assessing its presence. Ultrasound im-
aging may pick up fatty liver disease if about 30% of 
the liver is filled with fat making it unreliable. Liver 
biopsy remains the gold standard for both diagnosis and 
staging of the disease, but is not without risk. Although 
reliable, the process is costly requires significant exper-
tise and it is associated with complications such as 
bleeding and not insignificant pain even in the best 
hands.  Non-invasive, safe, low-cost, and highly reliable 
imaging techniques have been developed such as ultra-
sound-based transient elastography using the FibroScan 
machine (which is readily accepted by patients and pro-
viders). These hold tremendous promise in the clinical 
care of these patients around the world,but fibroscan  is 
currently non-existent in Ghana..   
 
Additionally, treatment decisions made based on liver 
function tests fail to capture disease severity in 
NAFLD.19 There are currently no approved pharmaco-
logical interventions for NAFLD, and current manage-
ment strategies aim to identify and treat features of the 
metabolic syndrome, in order to reduce long-term cardi-
ovascular and liver-related morbidity and mortality.20 
Features of the metabolic syndrome should be aggres-
sively managed, with a focus on weight loss. This is 
difficult to achieve in this population; even in highly 
supervised randomized clinical trials (RCTs), less than 
50% participants have been shown to achieve the ideal 
7% total body weight reduction.21 Tackling rising obesi-
ty levels requires a multi-faceted approach involving a 
range of activities including behavior change and access 
to weight management services. Changes to lifestyle, 
such as eating a healthy, balanced diet and regular phys-
ical activity, can help reduce levels of obesity (particu-
larly with reduction in carbohydrate content such as 
bread, rice, fufu and potatoes). Exercise as part of a 
healthy lifestyle has proven benefits to patients suffer-
ing from liver disease. There are several opportunities 
for public health nutrition and dietetic interventions to 
be put in place to support the prevention and reduction 
of obesity. The development of a locally agreed care 
pathway for patients with abnormal liver function tests 
and risk assessment of those incidentally found to have 
fatty liver disease. A simple and concise guidance to 
interpret abnormal liver function tests tool should be 
developed by the hepatologists for use in primary care, 
and steps taking to ensure its widespread use in all prac-
tices within the country. Opportunistic advice on life-
style changes including dietary advice and weight re-
duction in the appropriate individual should also be pro-
vided in all settings.   Obesity services and diabetology 
clinics should be involved to support the early detection 
and treatment of liver inflammation associated with 
fatty liver disease by referring appropriate patients.   
 
CONCLUSION 
NAFLD is a very common condition affecting approxi-
mately 30% of the population and can cause significant 
liver disease in a significant proportion of patients. Ac-
curate diagnosis and staging is important in determining 
the appropriate long-term management for patients with 
NAFLD. To mitigate this scourge, a dedicated   one-
stop-shop multidisciplinary fatty liver clinic is a neces-
sity in our environment. This should tackle the NAFLD 
problem from a 360 degree viewpoint and should in-
volve  different specialist services, including hepatolo-
gist, diabetologists, radiologists, dietician, psychologist, 
physical therapist, and nurses trained in liver care. Such 
a clinic can provide expert management targeted to-
wards those at highest risk of progressive liver disease, 
as well as access to emerging diagnostics and clinical 
trials. 
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